Abstract
RNA splicing dysregulation is considered as a molecular hallmark and important therapeutic target of cancer. While targeting splicing has been intensively pursued for cancer therapy, specific modulators for dysregulated splicing factors are generally lacking. RNA binding motif protein 10 (RBM10) is frequently mutated in multiple cancers, in particular lung adenocarcinoma. Increasing evidence demonstrates that RBM10 deficiency due to loss-of-function mutation or aberrant expression contributes to cancer development, progression and therapy response. Here we summarize the functional consequences and new therapeutic implications of RBM10 deficiency in cancer. Using RBM10 as a representative example, we highlight the main strategies and discuss the considerations of targeting dysregulated splicing factors for cancer therapy. Those strategies alone or in combination with currently approved therapies may hold great promise in cancer treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.